OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Want to cut your energy bills? Here’s how five experts are doing it 
WILMINGTON, Del., March 07, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of GW Pharmaceuticals plc (NASDAQ:GWPH)?
- Did you purchase your shares between December 4, 2014 and January 8, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of GW Pharmaceuticals plc (“GW Pharmaceuticals” or the “Company”) (NASDAQ:GWPH) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the American Depository Receipts (“ADRs”) of GW Pharmaceuticals between December 4, 2014 and January 8, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than March 21, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased ADRs of GW Pharmaceuticals during the Class Period, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/gw-pharmaceuticals-plc-gwph.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
